 OCALA, Fla., Sept. 07, 2022 GLOBE NEWSWIRE -- AIM ImmunoTech Inc. NYSE: American AIM AIM or the Company, an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D. Chief Executive Officer of AIM, will present at the virtual H.C. Wainwright 24 th Annual Global Investment Conference being held in New York, N.Y., and virtually, September 12-14, 2022. 